BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35982906)

  • 1. Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma.
    Gu X; Huang X; Zhang X; Wang C
    Int J Biol Sci; 2022; 18(13):4984-5000. PubMed ID: 35982906
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma.
    Liang L; Liu Y; Jiang S; Huang J; He H; Shen L; Cong L; Jiang Y
    J Immunol Res; 2022; 2022():6521290. PubMed ID: 35677538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
    Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
    Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
    Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
    J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel genome-wide DNA methylation profiling reveals distinct epigenetic landscape, prognostic model and cellular composition of early-stage lung adenocarcinoma.
    Gan J; Huang M; Wang W; Fu G; Hu M; Zhong H; Ye X; Cao Q
    J Transl Med; 2024 May; 22(1):428. PubMed ID: 38711158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis.
    Jiang X; Gao Y; Zhang N; Yuan C; Luo Y; Sun W; Zhang J; Ren J; Gong Y; Xie C
    Cell Transplant; 2020; 29():963689720977131. PubMed ID: 33334139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation- and homologous recombination deficiency-related mutant genes predict the prognosis of lung adenocarcinoma.
    Nie GJ; Liu J; Zou AM; Zhan SF; Liang JK; Sui Y; Chen YN; Yao WS
    J Clin Lab Anal; 2022 Apr; 36(4):e24277. PubMed ID: 35238419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
    Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
    Front Immunol; 2022; 13():960738. PubMed ID: 36032135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers.
    Li R; Yang YE; Yin YH; Zhang MY; Li H; Qu YQ
    J Transl Med; 2019 Sep; 17(1):324. PubMed ID: 31558162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
    Li H; Tong L; Tao H; Liu Z
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering N
    Zhu J; Wang M; Hu D
    Biomed Res Int; 2020; 2020():2514230. PubMed ID: 32258108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.